scholarly journals Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures

Seizure ◽  
2018 ◽  
Vol 58 ◽  
pp. 96-100 ◽  
Author(s):  
Weixing Feng ◽  
Shenghui Mei ◽  
Leting Zhu ◽  
Yazhen Yu ◽  
Weili Yang ◽  
...  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Farzad Akbarzadeh ◽  
Maryam Zolfaghari ◽  
Mohammad Reza Fayyazi Bordbar ◽  
Maliheh Dadgar Moghaddam ◽  
Maliheh Ziaee ◽  
...  

2020 ◽  
Vol 12 (4) ◽  
pp. 84-90
Author(s):  
O. A. Gromova ◽  
V. I. Demidov ◽  
A. G. Kalacheva ◽  
I. Yu. Torshin ◽  
T. R. Grishina ◽  
...  

Objective: to investigate the effect of dexketoprofen on the severity of seizures on a rat model of primary generalized seizures caused by thiosemicarbazide; to evaluate the neuroprotective effect of the drug.Material and methods. The investigation was conducted on 72 male albino rats weighing 200–300 g. The animals were given dexketoprofen and/or comparison drugs (gabapentin, sodium valproate) for 5 days, after which the seizure model was reproduced. The effects of the drugs were evaluated from a set of neurological tests and the results of a histopathological examination of the brain.Results and discussion. Dexketoprofen reduced the severity, duration, and number of primary generalized seizures and potentiated the anticonvulsant effects of gabapentin and sodium valproate. Histopathological and morphometric examinations of the rat brain showed that dexketoprofen inhibited the formation of irreversible neuronal changes (27.2%; control, 55.7%), by transferring them into reversible changes (47.7%; control, 21.8%).Conclusion. The investigation made it possible to conclude that dexketoprofen had a moderate neuroprotective effect neurologically and morphometrically verified.


2018 ◽  
Vol 3 (3) ◽  

Introduction: Too many patients with moderate to severe psoriasis do not receive adequate treatment. This means a vast undersupply in the treatment of patients with psoriasis. Only biologics fulfill the whole range of the treatment of psoriasis – psoriasis does not affect only skin but the whole organism: It is a systemic disease! Between the biologics are evident differences concerning the effect. Discussion: Based on broad personal experience in the management of patients with moderate to severe psoriasis new data from clinical studies with ixekizumab are examined. This contains new data on long-term-efficacy of ixekizumab, effectiveness in special localizations (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis) as well as safely data and experience on patients switched to ixekizumab from other biologics. Personal clinical experience is based on >300 non-selected outpatients with moderate to severe psoriasis, >250 patients on biological therapies, > 50 patients with ixekizumab. Conclusions: Focusing on a relevant number of patients switched from secukinumab to ixekizumab due to first or secondary loss of efficacy significant differences between both IL-17A-inhibitors mainly in terms of efficacy and speed of therapeutic response are shown. Finally the correlation between PASI-90-/PASI-100 response and significant changes in DLQI are highlighted.


2013 ◽  
Author(s):  
Sandra Belo ◽  
Claudia Nogueira ◽  
Susana Corujeira ◽  
Carla Costa ◽  
Cintia Castro-Correia ◽  
...  
Keyword(s):  

2018 ◽  
Author(s):  
Carolina Garcia-Figueras-Mateos ◽  
Manuel Cayon-Blanco

Sign in / Sign up

Export Citation Format

Share Document